No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
The Glucose Dependent Insulinotropic Receptor (GIPR) is a receptor found in the endocrine and metabolic disorders drugs market. It is a G-protein coupled receptor that is activated by glucose and is involved in the secretion of insulin. GIPR agonists are used to treat type 2 diabetes, as they can increase insulin secretion and reduce blood glucose levels. GIPR antagonists are also being developed to treat obesity and other metabolic disorders.
GIPR agonists are currently in clinical trials and have shown promising results in treating type 2 diabetes. GIPR antagonists are also being developed to treat obesity and other metabolic disorders.
Companies in the GIPR market include Novo Nordisk, Eli Lilly, Merck, Sanofi, and AstraZeneca. Show Less Read more
